‘UNLOCKING OUR POTENTIAL IN BIOSIMILAR SEGMENT’

“We have launched two products in the Indian market- Denosumab and Romisplostim and we have plans to further expand our portfolio going ahead. We have also made a good progress towards taking some of these products to regulated markets over the next five years which would be the key to unlocking our potential in the biosimilar segment.” - SANDEEP SINGH, Managing Director, Alkem Laboratories, Mumbai